Editor's note

This article was originally published on 6 February 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

A third flat year

According to VacZine Analytics calculations, the top five vaccine players reported approximately $20.7 billion in vaccine revenues in 2013, compared to nearly $21.4 billion in 2012 - a modest decline of approximately 3%. This is the third year running in which the vaccine industry has been essentially flat, awaiting its next burst of growth. Only life-cycle management initiatives - most notably the conversion to quadrivalent influenza formats - are generating meaningful pockets of revenue growth.

Top 5 FY2013 Sales
$20.7bn

Combined vaccine revenues for GSK, Sanofi Pasteur, Novartis, Merck and Pfizer in 2013

GSK: QIV doubles in Q4

GSK Biologicals again sold the most in dollar terms with $5.37 billion. The headline was quadrivalent influenza vaccine (Fluarix/FluLaval QIV), which "more than doubled" in Q4 US sales to £36 million and was up 76% globally at £87 million - benefiting from a 30-40% unit price premium over trivalent equivalents. Cervarix declined 37% due to Japan's suspension of HPV vaccination recommendations.

Sanofi: influenza surges 94% in Q4

Sanofi Pasteur recorded €3,716 million in 2013, a 4.8% reported decline. However, influenza vaccines showed an impressive 94.4% increase in Q4, reflecting US launch of QIV, Fluzone HD and Fluzone ID. New differentiated flu vaccines represented 41% of US influenza sales versus 26% in 2012. Other segments - meningitis, boosters - experienced double-digit declines.

Merck: growth across all franchises

Merck & Co was the standout for consistency, with growth across all vaccine franchises in 2013. Gardasil grew 12%, Zostavax 16% (benefiting from the UK shingles programme) and Pneumovax 13%. Zostavax reached $651 million globally.

Pfizer: Prevnar franchise edges lower

Pfizer's PCV-7/PCV-13 franchise registered $3,974 million in 2013, below the $4,267 million of 2012. Lifecycle management of the pneumococcal franchise through adult indications and the CAPiTA trial (results pending) was expected to stabilise the franchise in coming years.

"Only the launch of brand-new products matched to new national immunisation programmes will add billions to overall industry value."